Two randomized, double-blind studies demonstrated that a new antipsychotic treatment for adult patients with schizophrenia may lead to a meaningful reduction in symptoms.
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
Following a multicenter study, the FDA approved the combination of albuterol and budesonide—an inhaled corticosteroid—for the treatment of asthma in adults.
The recent FDA approval of a new oral treatment for patients with amyotrophic lateral sclerosis (ALS) adds another option for individuals who are diagnosed with the non-curable disease.